MetaCap

ICON (ICLR) vs MaxCyte (MXCT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ICON (ICLR) has outperformed MaxCyte (MXCT) over the past year, gaining 13.5% versus a loss of 18.0%. Over five years, ICLR leads with a -31.4% price change compared with -85.9% for MXCT. ICON is the larger company by market cap ($13.99 billion vs $141.5 million), about 98.9 times the size.

ICON converts more of its revenue into profit, with a net margin of 2.8% versus -135.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ICLR+13.46%MXCT-17.96%
+35%-14%-64%
Nov 21, 20251 yearNov 20, 2026
ICLR-34.76%MXCT-89.29%
+23%-39%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ICLR versus MXCT key metrics
MetricICLRMXCT
Share price$186.71$1.37
Market cap$13.99B$141.45M
1-day change-1.92%+7.03%
YTD return+2.46%-11.61%
1-year return+13.46%-17.96%
5-year return-31.36%-85.92%
P/E ratio (TTM)74.68—
Forward P/E16.09—
EPS (TTM)$2.50$-0.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$8.25B$33.03M
Revenue growth (YoY)+0.76%-14.50%
Net income (latest FY)$229.34M$-44.63M
Gross margin26.37%81.16%
Operating margin5.37%-157.14%
Net margin2.78%-135.14%
52-week high$219.04$1.80
52-week low$66.57$0.643
Distance from 52-week high-14.76%-23.89%
Analyst consensusbuystrong_buy
Avg. price target upside+23.88%+200.00%
Average volume989.87K1.04M
Shares outstanding74.92M103.25M
Employees40,25091
SectorHealth CareHealth Care
IndustryBiotechnology: Commercial Physical & Biological ResarchBiotechnology: Commercial Physical & Biological Resarch

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ICON is about 98.9 times larger than MaxCyte by market value ($13.99B vs $141.45M).
  • ICLR has outperformed MXCT by 31.4 percentage points over the past year.
  • ICON is more profitable, keeping 2.8 cents of every revenue dollar as net income versus -135.1 cents for MaxCyte.
  • ICON grew revenue faster in its latest fiscal year (+0.76% vs -14.50%).

About ICON

ICLR stock →

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 40,250 employees

About MaxCyte

MXCT stock →

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 91 employees

ICLR vs MXCT FAQ

Which is bigger, ICON or MaxCyte?

ICON (ICLR) is larger, with a market capitalization of $13.99B compared with $141.45M for MaxCyte (MXCT).

Which stock has performed better over the past year, ICLR or MXCT?

ICLR returned +13.46% over the past 12 months, compared with -17.96% for MXCT (price return, excluding dividends). Past performance does not predict future results.

Are ICON and MaxCyte in the same industry?

Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.

More comparisons